MB Venture Partners
Gary Stevenson, Co-Founder and Managing Partner
Gary Stevenson co-founded MB Venture Partners in 2001 after six years in healthcare investment banking and equity research. At MBVP, he has raised $120 million in committed capital to four funds and invested in more than 50 start-ups, most of which are focused on product solutions for musculoskeletal disease. He also spent seven years in a variety of general management roles with Abbott Laboratories. Gary holds an undergraduate degree in accounting from the University of Missouri. He also received an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University. He is a certified public accountant and a chartered financial analyst. Gary is a board member or observer for several MBVP portfolio companies. Medtronic, Smith + Nephew, Zimmer Biomet, and Wright Medical have each acquired MBVP-funded start-ups. This will be his 18th year to host the MNVC.
Kyle Rose, Managing Director | Healthcare Equity Research
Kyle Rose has been a member of Canaccord Genuity’s medical technology research team since 2010 and is the senior analyst responsible for covering the orthopedics, diabetes, aesthetics and ENT sectors. Prior to joining Canaccord Genuity, Kyle worked as an associate product manager for Zimmer Biomet (formerly Biomet Microfixation), a medical device manufacturer focusing on the craniomaxillofacial, neurosurgery, and cardiothoracic markets. Kyle holds an MBA from the Kellogg School of Management at Northwestern University as well as a BA from the University of Michigan.
Beau Standish- Chief Executive Officer and Steve Martin- Chief Financial Officer
7D Surgical is a privately-owned Toronto based company that develops advanced optical technologies and machine vision-based registration algorithms to improve surgical workflow and patient care. 7D Surgical’s flagship FDA 510(k)-cleared and Health Canada approved MvIGS system delivers profound improvement to surgical workflows in spine and cranial surgeries. The underlying technology provides the promise of similar future advancements for other surgical specialties.
Albert DaCosta, President & Chief Executive Officer
Matt Jarboe, Co-founder and Chief Commercial Officer
From the onset, Paragon 28® has made it our goal to re-invent the space of foot and ankle surgery. It is not enough for us to develop products. The key is to think about how every foot and ankle problem is addressed and ask questions. Why is the procedure done that way? How can we streamline the procedure and make it more easily reproduced? How can we lower surgeon anxiety when dealing with specific, complex procedures? Where can techniques and solutions available for less researched procedures be improved? We emphasize the philosophy of innovation through design and carry that through for the entire procedure. To us, it’s more than just a locking screw or a surgical plate; it’s an entire system that makes foot and ankle surgery go more smoothly. Paragon 28® continually makes efforts toward broad market distribution and extensive product knowledge. Superior product knowledge is beneficial to all parties, and is something for which we strive. We recruit, train and hire a sales and distribution network of the most highly educated, knowledgeable and respected sales representatives in the foot and ankle market. The sales representatives’ education is extensive and on-going, with opportunities for sales representatives to continually grow and learn to become an excellent source of product support for the foot and ankle surgeon in the operating room.
Mike Cordonnier, CEO and Co-founder
Sharon Schulzki, COO
Carlsmed is a San Diego based company and has developed a proprietary digital + surgical solution for spine surgery and beyond. The Carlsmed aprevo™️ device has the potential to improve the standard of care for spine surgery by using data to create surgical plans and personalized spine deformity correction implants on demand.
Jeff Conroy, CEO
Rob Brown, Chief Commercial Officer
Embody is a sports medicine medical device company developing collagen-based implants for the treatment of tendon and ligament injuries. Embody will launch the Tapestry Biointegrative Implant following FDA 510(k) clearance in October 2020. Embody will launch four products over the next three years. Embody has been funded by DARPA and the Department of Defense with over $20 million in non-dilutive funding and has previously raised $9.3 million in Series A financing. As we become a growth-stage investment, we are seeking $15 million Series B funding to accelerate commercial adoption and product development.